167 related articles for article (PubMed ID: 35686890)
1. Comment on: Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study: Reply.
Pina Vegas L; Claudepierre P; Sbidian E
Rheumatology (Oxford); 2022 Oct; 61(10):e321-e322. PubMed ID: 35686890
[No Abstract] [Full Text] [Related]
2. Comment on: Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study: Reply.
Pina Vegas L; Claudepierre P; Sbidian E
Rheumatology (Oxford); 2022 Aug; 61(8):e238-e239. PubMed ID: 35333297
[No Abstract] [Full Text] [Related]
3. Comment on: Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study.
Ouyang F
Rheumatology (Oxford); 2022 Oct; 61(10):e320. PubMed ID: 35686859
[No Abstract] [Full Text] [Related]
4. Comment on: Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study.
Suruki RY; Desai RJ; Davis KJ; Berlin JA; Gagne JJ
Rheumatology (Oxford); 2022 Aug; 61(8):e236-e237. PubMed ID: 35333307
[No Abstract] [Full Text] [Related]
5. Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study.
Pina Vegas L; Le Corvoisier P; Penso L; Paul M; Sbidian E; Claudepierre P
Rheumatology (Oxford); 2022 Apr; 61(4):1589-1599. PubMed ID: 34244706
[TBL] [Abstract][Full Text] [Related]
6. Combination Therapy of Apremilast and Biologic Agent as a Safe Option of Psoriatic Arthritis and Psoriasis.
Metyas S; Tomassian C; Messiah R; Gettas T; Chen C; Quismorio A
Curr Rheumatol Rev; 2019; 15(3):234-237. PubMed ID: 30499418
[TBL] [Abstract][Full Text] [Related]
7. Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis.
Wu JJ; Pelletier C; Ung B; Tian M; Khilfeh I; Curtis JR
Adv Ther; 2020 May; 37(5):2098-2115. PubMed ID: 32141018
[TBL] [Abstract][Full Text] [Related]
8. Treatment patterns and costs among biologic-naive patients initiating apremilast or biologics for psoriatic arthritis.
Feldman SR; Pelletier CL; Wilson KL; Mehta RK; Brouillette MA; Smith D; Bonafede MM
J Comp Eff Res; 2019 Jul; 8(9):699-709. PubMed ID: 31081676
[No Abstract] [Full Text] [Related]
9. Safety of Apremilast in Patients with Psoriasis and Psoriatic Arthritis: Findings from the UK Clinical Practice Research Datalink.
Persson R; Cordey M; Paris M; Jick S
Drug Saf; 2022 Nov; 45(11):1403-1411. PubMed ID: 36151359
[TBL] [Abstract][Full Text] [Related]
10. ▼ Apremilast for psoriasis and psoriatic arthritis.
Drug Ther Bull; 2015 Sep; 53(9):105-8. PubMed ID: 26358317
[TBL] [Abstract][Full Text] [Related]
11. New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast.
Palfreeman AC; McNamee KE; McCann FE
Drug Des Devel Ther; 2013; 7():201-10. PubMed ID: 23569359
[TBL] [Abstract][Full Text] [Related]
12. Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
Keating GM
Drugs; 2017 Mar; 77(4):459-472. PubMed ID: 28213862
[TBL] [Abstract][Full Text] [Related]
13. Apremilast efficacy and safety in a psoriatic arthritis patient affected by HIV and HBV virus infections.
Manfreda V; Esposito M; Campione E; Bianchi L; Giunta A
Postgrad Med; 2019 Apr; 131(3):239-240. PubMed ID: 30700196
[TBL] [Abstract][Full Text] [Related]
14. Apremilast in the treatment of psoriasis and psoriatic arthritis.
Gooderham M; Papp K
Skin Therapy Lett; 2015; 20(5):1-6. PubMed ID: 26382906
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and Drug Survival of Apremilast in 65 Patients With Psoriasis and/or Psoriatic Arthritis.
Garbayo Salmons P; Expósito Serrano V; Romaní de Gabriel J; Ribera Pibernat M
Actas Dermosifiliogr; 2022 May; 113(5):532-535. PubMed ID: 35697416
[No Abstract] [Full Text] [Related]
16. Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis.
Wu JJ; Pelletier C; Ung B; Tian M
J Med Econ; 2019 Apr; 22(4):365-371. PubMed ID: 30652520
[TBL] [Abstract][Full Text] [Related]
17. Apremilast increases IL-10-producing regulatory B cells and decreases proinflammatory T cells and innate cells in psoriatic arthritis and psoriasis.
Mavropoulos A; Zafiriou E; Simopoulou T; Brotis AG; Liaskos C; Roussaki-Schulze A; Katsiari CG; Bogdanos DP; Sakkas LI
Rheumatology (Oxford); 2019 Dec; 58(12):2240-2250. PubMed ID: 31209492
[TBL] [Abstract][Full Text] [Related]
18. Risk of Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis/Ankylosing Spondylitis Initiating Interleukin-17 Inhibitors: A Nationwide Population-Based Study Using the French National Health Data System.
Penso L; Bergqvist C; Meyer A; Herlemont P; Weill A; Zureik M; Dray-Spira R; Sbidian E
Arthritis Rheumatol; 2022 Feb; 74(2):244-252. PubMed ID: 34279061
[TBL] [Abstract][Full Text] [Related]
19. The Effects of Apremilast Therapy on Deployability in Active Duty US Army Soldiers With Plaque Psoriasis and Psoriatic Arthritis.
Price AD; Wagler VD; Donaldson C; Mastin PJ
J Clin Rheumatol; 2021 Apr; 27(3):127-128. PubMed ID: 33136692
[No Abstract] [Full Text] [Related]
20. The risk of treated anxiety and treated depression among patients with psoriasis and psoriatic arthritis treated with apremilast compared to biologics, DMARDs and corticosteroids: a cohort study in the United States MarketScan database.
Vasilakis-Scaramozza C; Persson R; Hagberg KW; Jick S
J Eur Acad Dermatol Venereol; 2020 Aug; 34(8):1755-1763. PubMed ID: 31981426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
